Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer
The objective of our study was to analyze quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires. A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female pati...
Gespeichert in:
| Veröffentlicht in: | Clinical breast cancer 2022-04, Vol.22 (3), p.e352-e361 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e361 |
|---|---|
| container_issue | 3 |
| container_start_page | e352 |
| container_title | Clinical breast cancer |
| container_volume | 22 |
| creator | Benoit, Louise Cambra, Carine Rouzier, Roman Cottu, Paul Rodrigues, Manuel Reyal, Fabien Research Network, Seintinelles Bonneau, Claire |
| description | The objective of our study was to analyze quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires.
A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female patients treated for nonmetastatic and nonrecurrent BC, treated in France after 2005, filled in online questionnaires concerning: QOL (QLQ-C30 and QLQ-BR23), tolerability of treatment and demographic characteristics. A multivariate analysis including variables significant on univariate analysis (P < .05) to select QOL predictors was performed.
We included 1,198 patients, 1140 of whom declared that they were taking ET (37.7% tamoxifen, 17.1% aromatase inhibitor (AI), 5.6% LHRH-agonist and 39.6% sequential tamoxifen and AI). Different tolerability profiles were observed when comparing the tamoxifen and AI groups. Treatment adherence was similar in the 2 groups. QOL varied slightly according to the type of ET. On multivariate analysis, ET had no impact on QOL. However, individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL
Using a real-life study questionnaire on a large e-cohort, individual patient characteristics were strongly associated with deterioration of QOL. The use of e-cohorts must be encouraged to modulate the conclusions of randomized trials.
Quality of life (QOL) was assessed in an e-cohort of patients treated for breast cancer by endocrine therapy, by means of validated quality of life questionnaires. Endocrine therapy does not alter QOL. Individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL. The use of e-cohorts must be encouraged to study patient reported outcomes without medical inference. |
| doi_str_mv | 10.1016/j.clbc.2021.09.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03642650v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1526820921002913</els_id><sourcerecordid>2596014632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-b18d5922149545077d6a04916395b4bca453d91e104312e5cf67f92b080fb3973</originalsourceid><addsrcrecordid>eNp9kUtr3DAUhUVpaB7tH-iiaNku7Fw9bUE36TBJCgOlMKWbgpDla0aDx5pKnoD_fWwmzbKrezl85yzOIeQjg5IB07f70veNLzlwVoIpgfE35IoZURegtX47_4rrouZgLsl1znsArgWDd-RSyEppXesr8ufnyfVhnGjs6CZ0SMNA3UCxWMVdTOMi_44HHOg2oRuxpc1E10MbfQoD0u0OkztOtIuJrl3qJ_ptxvJIV27wmN6Ti871GT-83Bvy6369XT0Wmx8P31d3m8JLIceiYXWrDOdMGiUVVFWrHUjDtDCqkY13UonWMGQgBeOofKerzvAGaugaYSpxQ76cc3eut8cUDi5NNrpgH-82dtFAaMm1gic2s5_P7DHFvyfMoz2E7LHv3YDxlC1XRgOTWvAZ5WfUp5hzwu41m4FdFrB7uyxglwUsGDsvMJs-veSfmgO2r5Z_lc_A1zOAcyNPAZPNPuBcVxsS-tG2Mfwv_xlB3pN6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596014632</pqid></control><display><type>article</type><title>Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Benoit, Louise ; Cambra, Carine ; Rouzier, Roman ; Cottu, Paul ; Rodrigues, Manuel ; Reyal, Fabien ; Research Network, Seintinelles ; Bonneau, Claire</creator><creatorcontrib>Benoit, Louise ; Cambra, Carine ; Rouzier, Roman ; Cottu, Paul ; Rodrigues, Manuel ; Reyal, Fabien ; Research Network, Seintinelles ; Bonneau, Claire</creatorcontrib><description>The objective of our study was to analyze quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires.
A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female patients treated for nonmetastatic and nonrecurrent BC, treated in France after 2005, filled in online questionnaires concerning: QOL (QLQ-C30 and QLQ-BR23), tolerability of treatment and demographic characteristics. A multivariate analysis including variables significant on univariate analysis (P < .05) to select QOL predictors was performed.
We included 1,198 patients, 1140 of whom declared that they were taking ET (37.7% tamoxifen, 17.1% aromatase inhibitor (AI), 5.6% LHRH-agonist and 39.6% sequential tamoxifen and AI). Different tolerability profiles were observed when comparing the tamoxifen and AI groups. Treatment adherence was similar in the 2 groups. QOL varied slightly according to the type of ET. On multivariate analysis, ET had no impact on QOL. However, individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL
Using a real-life study questionnaire on a large e-cohort, individual patient characteristics were strongly associated with deterioration of QOL. The use of e-cohorts must be encouraged to modulate the conclusions of randomized trials.
Quality of life (QOL) was assessed in an e-cohort of patients treated for breast cancer by endocrine therapy, by means of validated quality of life questionnaires. Endocrine therapy does not alter QOL. Individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL. The use of e-cohorts must be encouraged to study patient reported outcomes without medical inference.</description><identifier>ISSN: 1526-8209</identifier><identifier>EISSN: 1938-0666</identifier><identifier>DOI: 10.1016/j.clbc.2021.09.012</identifier><identifier>PMID: 34756686</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Agents, Hormonal - adverse effects ; Aromatase Inhibitors - adverse effects ; Breast Neoplasms - pathology ; breat cancer ; Cohort Studies ; e-cohort ; endocrine therapy ; Female ; Humans ; Life Sciences ; Quality of Life ; questionnaire ; Retrospective Studies ; Tamoxifen - therapeutic use</subject><ispartof>Clinical breast cancer, 2022-04, Vol.22 (3), p.e352-e361</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-b18d5922149545077d6a04916395b4bca453d91e104312e5cf67f92b080fb3973</citedby><cites>FETCH-LOGICAL-c434t-b18d5922149545077d6a04916395b4bca453d91e104312e5cf67f92b080fb3973</cites><orcidid>0000-0002-5443-0802 ; 0000-0002-0871-1793 ; 0000-0001-6434-3932 ; 0000-0001-6251-286X ; 0000-0002-8167-6808 ; 0000-0002-2318-3589</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clbc.2021.09.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34756686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03642650$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Benoit, Louise</creatorcontrib><creatorcontrib>Cambra, Carine</creatorcontrib><creatorcontrib>Rouzier, Roman</creatorcontrib><creatorcontrib>Cottu, Paul</creatorcontrib><creatorcontrib>Rodrigues, Manuel</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><creatorcontrib>Research Network, Seintinelles</creatorcontrib><creatorcontrib>Bonneau, Claire</creatorcontrib><title>Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer</title><title>Clinical breast cancer</title><addtitle>Clin Breast Cancer</addtitle><description>The objective of our study was to analyze quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires.
A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female patients treated for nonmetastatic and nonrecurrent BC, treated in France after 2005, filled in online questionnaires concerning: QOL (QLQ-C30 and QLQ-BR23), tolerability of treatment and demographic characteristics. A multivariate analysis including variables significant on univariate analysis (P < .05) to select QOL predictors was performed.
We included 1,198 patients, 1140 of whom declared that they were taking ET (37.7% tamoxifen, 17.1% aromatase inhibitor (AI), 5.6% LHRH-agonist and 39.6% sequential tamoxifen and AI). Different tolerability profiles were observed when comparing the tamoxifen and AI groups. Treatment adherence was similar in the 2 groups. QOL varied slightly according to the type of ET. On multivariate analysis, ET had no impact on QOL. However, individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL
Using a real-life study questionnaire on a large e-cohort, individual patient characteristics were strongly associated with deterioration of QOL. The use of e-cohorts must be encouraged to modulate the conclusions of randomized trials.
Quality of life (QOL) was assessed in an e-cohort of patients treated for breast cancer by endocrine therapy, by means of validated quality of life questionnaires. Endocrine therapy does not alter QOL. Individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL. The use of e-cohorts must be encouraged to study patient reported outcomes without medical inference.</description><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Aromatase Inhibitors - adverse effects</subject><subject>Breast Neoplasms - pathology</subject><subject>breat cancer</subject><subject>Cohort Studies</subject><subject>e-cohort</subject><subject>endocrine therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Quality of Life</subject><subject>questionnaire</subject><subject>Retrospective Studies</subject><subject>Tamoxifen - therapeutic use</subject><issn>1526-8209</issn><issn>1938-0666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtr3DAUhUVpaB7tH-iiaNku7Fw9bUE36TBJCgOlMKWbgpDla0aDx5pKnoD_fWwmzbKrezl85yzOIeQjg5IB07f70veNLzlwVoIpgfE35IoZURegtX47_4rrouZgLsl1znsArgWDd-RSyEppXesr8ufnyfVhnGjs6CZ0SMNA3UCxWMVdTOMi_44HHOg2oRuxpc1E10MbfQoD0u0OkztOtIuJrl3qJ_ptxvJIV27wmN6Ti871GT-83Bvy6369XT0Wmx8P31d3m8JLIceiYXWrDOdMGiUVVFWrHUjDtDCqkY13UonWMGQgBeOofKerzvAGaugaYSpxQ76cc3eut8cUDi5NNrpgH-82dtFAaMm1gic2s5_P7DHFvyfMoz2E7LHv3YDxlC1XRgOTWvAZ5WfUp5hzwu41m4FdFrB7uyxglwUsGDsvMJs-veSfmgO2r5Z_lc_A1zOAcyNPAZPNPuBcVxsS-tG2Mfwv_xlB3pN6</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Benoit, Louise</creator><creator>Cambra, Carine</creator><creator>Rouzier, Roman</creator><creator>Cottu, Paul</creator><creator>Rodrigues, Manuel</creator><creator>Reyal, Fabien</creator><creator>Research Network, Seintinelles</creator><creator>Bonneau, Claire</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-5443-0802</orcidid><orcidid>https://orcid.org/0000-0002-0871-1793</orcidid><orcidid>https://orcid.org/0000-0001-6434-3932</orcidid><orcidid>https://orcid.org/0000-0001-6251-286X</orcidid><orcidid>https://orcid.org/0000-0002-8167-6808</orcidid><orcidid>https://orcid.org/0000-0002-2318-3589</orcidid></search><sort><creationdate>20220401</creationdate><title>Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer</title><author>Benoit, Louise ; Cambra, Carine ; Rouzier, Roman ; Cottu, Paul ; Rodrigues, Manuel ; Reyal, Fabien ; Research Network, Seintinelles ; Bonneau, Claire</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-b18d5922149545077d6a04916395b4bca453d91e104312e5cf67f92b080fb3973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Aromatase Inhibitors - adverse effects</topic><topic>Breast Neoplasms - pathology</topic><topic>breat cancer</topic><topic>Cohort Studies</topic><topic>e-cohort</topic><topic>endocrine therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Quality of Life</topic><topic>questionnaire</topic><topic>Retrospective Studies</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benoit, Louise</creatorcontrib><creatorcontrib>Cambra, Carine</creatorcontrib><creatorcontrib>Rouzier, Roman</creatorcontrib><creatorcontrib>Cottu, Paul</creatorcontrib><creatorcontrib>Rodrigues, Manuel</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><creatorcontrib>Research Network, Seintinelles</creatorcontrib><creatorcontrib>Bonneau, Claire</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Clinical breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benoit, Louise</au><au>Cambra, Carine</au><au>Rouzier, Roman</au><au>Cottu, Paul</au><au>Rodrigues, Manuel</au><au>Reyal, Fabien</au><au>Research Network, Seintinelles</au><au>Bonneau, Claire</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer</atitle><jtitle>Clinical breast cancer</jtitle><addtitle>Clin Breast Cancer</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>22</volume><issue>3</issue><spage>e352</spage><epage>e361</epage><pages>e352-e361</pages><issn>1526-8209</issn><eissn>1938-0666</eissn><abstract>The objective of our study was to analyze quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires.
A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female patients treated for nonmetastatic and nonrecurrent BC, treated in France after 2005, filled in online questionnaires concerning: QOL (QLQ-C30 and QLQ-BR23), tolerability of treatment and demographic characteristics. A multivariate analysis including variables significant on univariate analysis (P < .05) to select QOL predictors was performed.
We included 1,198 patients, 1140 of whom declared that they were taking ET (37.7% tamoxifen, 17.1% aromatase inhibitor (AI), 5.6% LHRH-agonist and 39.6% sequential tamoxifen and AI). Different tolerability profiles were observed when comparing the tamoxifen and AI groups. Treatment adherence was similar in the 2 groups. QOL varied slightly according to the type of ET. On multivariate analysis, ET had no impact on QOL. However, individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL
Using a real-life study questionnaire on a large e-cohort, individual patient characteristics were strongly associated with deterioration of QOL. The use of e-cohorts must be encouraged to modulate the conclusions of randomized trials.
Quality of life (QOL) was assessed in an e-cohort of patients treated for breast cancer by endocrine therapy, by means of validated quality of life questionnaires. Endocrine therapy does not alter QOL. Individual patient characteristics (socioeconomic, education and age) were significantly associated with QOL. The use of e-cohorts must be encouraged to study patient reported outcomes without medical inference.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34756686</pmid><doi>10.1016/j.clbc.2021.09.012</doi><orcidid>https://orcid.org/0000-0002-5443-0802</orcidid><orcidid>https://orcid.org/0000-0002-0871-1793</orcidid><orcidid>https://orcid.org/0000-0001-6434-3932</orcidid><orcidid>https://orcid.org/0000-0001-6251-286X</orcidid><orcidid>https://orcid.org/0000-0002-8167-6808</orcidid><orcidid>https://orcid.org/0000-0002-2318-3589</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-8209 |
| ispartof | Clinical breast cancer, 2022-04, Vol.22 (3), p.e352-e361 |
| issn | 1526-8209 1938-0666 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03642650v1 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antineoplastic Agents, Hormonal - adverse effects Aromatase Inhibitors - adverse effects Breast Neoplasms - pathology breat cancer Cohort Studies e-cohort endocrine therapy Female Humans Life Sciences Quality of Life questionnaire Retrospective Studies Tamoxifen - therapeutic use |
| title | Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20Life%20in%20an%20e-Cohort%20of%20Women%20Treated%20by%20Endocrine%20Therapy%20for%20Early%20Breast%20Cancer&rft.jtitle=Clinical%20breast%20cancer&rft.au=Benoit,%20Louise&rft.date=2022-04-01&rft.volume=22&rft.issue=3&rft.spage=e352&rft.epage=e361&rft.pages=e352-e361&rft.issn=1526-8209&rft.eissn=1938-0666&rft_id=info:doi/10.1016/j.clbc.2021.09.012&rft_dat=%3Cproquest_hal_p%3E2596014632%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2596014632&rft_id=info:pmid/34756686&rft_els_id=S1526820921002913&rfr_iscdi=true |